Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...

Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026Pivotal ...

Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory ...

ON THIS PAGEPhysical Therapy vs. General ExerciseEssential LEMS ExercisesAssistive Tools and Home ModificationsIf youre living with Lambert-Eaton myasthenic syndrome (LEMS), you may notice that your ...

After the FDA’s first-ever public listening meeting on data-sharing in the cell and gene therapy space, new draft guidance aims to standardize the practice. But recent decisions call into question ...

Bureaucracy's Rot Runs Amok at FDA ...

Scholar Rock’s latest earnings call struck a cautiously optimistic tone, with management emphasizing regulatory traction, a deepening neuromuscular pipeline, and a visibly maturing commercial ...

Need motivation to stay active in your golden years? Accumulating evidence suggests that about 22 minutes of moderate-intensity exercise per day (150 mins/week) can significantly increase your odds of ...